

# INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability

<https://marketpublishers.com/r/I14763D4996EN.html>

Date: May 2012

Pages: 3

Price: US\$ 140.00 (Single User License)

ID: I14763D4996EN

## Abstracts

Incyte (INCY) reported net revenues of \$19.3m of the only approved drug for Myelofribrosis (MF), JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET; partnered with Novartis for Ex-US rights) in the 1Q12. We expect strong but gradual uptake in “intermediate or high-risk” pts (80-90% of all MF pts) based on its compelling efficacy and safety data. Label expansion in other Myeloproliferative Neoplasms’ (MPN) indications: Advanced Polycythemia Vera (PV, PhIII) and Essential Thrombocythemia (ET, PhII) should bring INCY closer towards profitability. Support of two global partners – Novartis and Lilly and upcoming catalysts in 2013, INCY is ... For more details, please read our report released on May 2, 2012 on INCY, titled “JAKAFI / JAKAVI to Drive Sustainable Profitability”

## Contents

### COMPANIES MENTIONED

INCYTE

## I would like to order

Product name: INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability

Product link: <https://marketpublishers.com/r/l14763D4996EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l14763D4996EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970